Havrix

Havrix is an injectable solution containing the inactivated hepatitis A virus adsorbed on aluminium hydroxide hydrated, produced on human diploid cells. It is supplied without a specified strength and is administered intramuscularly. Classified as a vaccine (ATC code J07BC01), Havrix is prescribed for hepatitis A prophylaxis in the European market. It stimulates the immune system to produce antibodies that protect against hepatitis A infection, useful for travelers and outbreak control.

Havrix is indicated for active immunization against hepatitis A virus in several clinical situations.

- Prevention of hepatitis A infection in individuals at increased risk, such as those with chronic liver disease. - Pre‑travel protection for persons traveling to regions where hepatitis A is endemic. - Immunization of close contacts during hepatitis A outbreak investigations. - Post‑exposure prophylaxis for individuals who have been exposed to hepatitis A and are not immune. - Routine vaccination of children and adolescents according to national immunization schedules where applicable.

The safety profile of Havrix reflects the typical reactions seen with inactivated vaccines, most of which are mild and self‑limiting.

Common: - Pain, redness, or swelling at the injection site. - Mild fever. - Headache.

Serious: - Severe allergic reaction (anaphylaxis) with breathing difficulty or swelling. - Guillain‑Barré syndrome, a rare neurological disorder. - High‑grade fever lasting more than 48 hours.

Before administering Havrix, healthcare providers should consider several precautionary measures to ensure safe use.

- Do not vaccinate individuals with a known severe allergy to any component of the vaccine. - Defer vaccination in persons who have experienced a severe allergic reaction to a previous dose of Havrix. - Use with caution in pregnant or breastfeeding women; benefits should outweigh potential risks. - Evaluate immunocompromised patients individually, as response may be reduced. - Monitor for signs of anaphylaxis for at least 15 minutes after injection. - Postpone vaccination in persons with acute moderate or severe illness until recovery.

Havrix has limited known drug interactions, but certain substances may affect its administration or immune response.

Avoid: - Concurrent administration of other injectable vaccines at the same anatomical site, which may increase local reactions. - Simultaneous administration with live attenuated vaccines at the same site.

Use with caution: - Immunoglobulin or blood products given within 2 weeks before or after vaccination, as they may blunt antibody response. - Systemic corticosteroids or other immunosuppressive therapies, which could reduce vaccine efficacy. - Antipyretics (e.g., acetaminophen) taken prophylactically before vaccination, as they might diminish antibody production. - Live vaccines administered within 4 weeks before or after Havrix should be spaced appropriately to avoid interference.